Developing a multivariable prognostic model for pancreatic endocrine tumors using the clinical data warehouse resources of a single institution
23 December 2009
accepted: 10 March 2010
16 December 2017 (online)
Objective: Current staging systems are not accurate for classifying pancreatic endocrine tumors (PETs) by risk. Here, we developed a prognostic model for PETs and compared it to the WHO classification system.
Methods: We identified 98 patients diagnosed with PET at NewYork-Presbyterian Hospital/Columbia University Medical Center (1999 to 2009). Tumor and clinical characteristics were retrieved and associations with survival were assessed by univariate Cox analysis. A multivariable model was constructed and a risk score was calculated; the prognostic strength of our model was assessed with the concordance index.
Results: Our cohort had median age of 60 years and consisted of 61.2% women; median follow-up time was 10.4 months (range: 0.1-99.6) with a 5-year survival of 61.5%. The majority of PETs were non-functional and no difference was observed between functional and non-functional tumors with respect to WHO stage, age, pathologic characteristics or survival. Distant metastases, aspartate aminotransferase-AST and surgical resection (HR=3.39, 95% CI: 1.38-8.35, p=0.008, HR=3.73, 95% CI: 1.20-11.57, p=0.023 and HR=0.20, 95% CI: 0.08-0.51, p<0.001 respectively) were the strongest predictors in the univariate analysis. Age, perineural and/or lymphovascular invasion, distant metastases and AST were the independent prognostic factors in the final multivariable model; a risk score was calculated and classified patients into low (n=40), intermediate (n=48) and high risk (n=10) groups. The concordance index of our model was 0.93 compared to 0.72 for the WHO system.
Conclusion: Our prognostic model was highly accurate in stratifying patients by risk; novel approaches as such could thus be incorporated into clinical decisions.
- 1 Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.. Endocr Relat Cancer 2008; 15: 409.
- 2 Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases.. Dig Dis Sci 1991; 36: 933.
- 3 Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material.. Virchows Arch A Pathol Anat Histol 1975; 365: 275.
- 4 Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors.. Cancer 1997; 79: 813.
- 5 Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients.. J Gastrointest Surg 1998; 2: 473.
- 6 Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.. Ann Oncol 2008; 19: 1727.
- 7 Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.. Ann N Y Acad Sci 2004; 1014: 13.
- 8 Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.. J Clin Oncol 2002; 20: 2633.
- 9 Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.. Virchows Arch 2006; 449: 395.
- 10 Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.. Ann Surg 2008; 247: 490.
- 11 Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study.. Mayo Clin Proc 1991; 66: 711.
- 12 van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis.. Stat Med 1999; 18: 681.
- 13 Austin PC, Tu JV. Bootstrap methods fof developing predictive models.. The American Statistician 2004; 52: 131.
- 14 Harrell Jr., FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests.. JAMA 1982; 247: 2543.
- 15 Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, Klimstra DS, Allen PJ. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?. J Clin Oncol 2007; 25: 5609.
- 16 Chu QD, Hill HC, Douglass Jr., HO, Driscoll D, Smith JL, Nava HR, Gibbs JF. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.. Ann Surg Oncol 2002; 9: 855.
- 17 Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pezzilli R, Corinaldesi R. Endocrine pancreatic tumors: factors correlated with survival.. Ann Oncol 2005; 16: 1806.
- 18 Tsuchiya A, Koizumi M, Ohtani H. World Health Organization Classification (2004)-based re-evaluation of 95 nonfunctioning "malignant" pancreatic endocrine tumors reported in Japan.. Surg Today 2009; 39: 500.
- 19 Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Buchler MW. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.. Br J Surg 2008; 95: 627.
- 20 Chung JC, Choi DW, Jo SH, Heo JS, Choi SH, Kim YI. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment.. World J Surg 2007; 31: 579.
- 21 Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases.. Arch Surg 2006; 141: 765.
- 22 Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help?. World J Surg 2000; 24: 1312.
- 23 Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.. Clin Cancer Res 2008; 14: 7798.
- 24 Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernandez-Del Castillo C. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005.. Arch Surg 2007; 142: 347.
- 25 Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.. Dig Dis Sci 2006; 51: 877.
- 26 Ali A, Serra S, Asa SL, Chetty R. The predictive value of CK19 and CD99 in pancreatic endocrine tumors.. Am J Surg Pathol 2006; 30: 1588.
- 27 Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, ProbstHensch NM, Moch H, Heitz PU, Kloeppel G, Komminoth P, Perren A. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.. Am J Surg Pathol 2007; 31: 1677.
- 28 La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C, Solcia E. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.. Hum Pathol 2009; 40: 30.
- 29 van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example.. J Clin Epidemiol 2006; 59: 1102.
- 30 Arnold AM, Kronmal RA. Multiple imputation of baseline data in the cardiovascular health study.. Am J Epidemiol 2003; 157: 74.
- 31 Clark TG, Altman DG. Developing a prognostic model in the presence of missing data: an ovarian cancer case study.. J Clin Epidemiol 2003; 56: 28.
- 32 Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer.. Br J Cancer 2001; 85: 944.